Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 3:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vaccinations Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

NCT02743455
View directory record Official record
Conditions
Yellow Fever, Yellow Fever Immunisation
Interventions
ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine, Placebo, YF Vax 17D Strain
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jun 10, 2026, 3:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

NCT03318315
View directory record Official record
Conditions
Avian Influenza, Influenza, Influenza Immunisation
Interventions
AS03, Inactivated influenza H7N9 vaccine, Influenza Virus Quadrivalent Inactivated Vaccine, Phosphate Buffered Saline (PBS) diluent
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 64 Years
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Birmingham, Alabama • Baltimore, Maryland • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Jun 10, 2026, 3:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Tdap Vaccination for Infant Caregivers

NCT01233401
View directory record Official record
Conditions
Pertussis, Vaccination
Interventions
Survey
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 64 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 27, 2011 · Synced Jun 10, 2026, 3:46 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Malignant Glioma

NCT00612001
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Jun 10, 2026, 3:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Development of Childhood Anti-Influenza Immunity

NCT03673345
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Virus Quadrivalent Inactivated Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 15 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Jun 10, 2026, 3:46 PM EDT
Recruiting Phase 2 Interventional

Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance

NCT06343077
View directory record Official record
Conditions
Prostate Cancer Patients on Active Surveillance
Interventions
Poly-ICLC intramuscular (IM) injection, Poly-ICLC, Intertumoral (IT) injection
Drug
Lead sponsor
Ashutosh Kumar Tewari
Other
Eligibility
18 Years and older · Male only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Jun 10, 2026, 3:46 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model

NCT01397227
View directory record Official record
Conditions
Malaria
Interventions
Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp), Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp), Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Jun 10, 2026, 3:46 PM EDT
Completed Phase 1 Interventional

Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma

NCT01264731
View directory record Official record
Conditions
Melanoma
Interventions
MELITAC 12.1, Imiquimod
Biological · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Jun 10, 2026, 3:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection

NCT03453801
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Fluzone®, FluMist®
Biological
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 10 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Jun 10, 2026, 3:46 PM EDT
Terminated Early Phase 1 Interventional

Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia

NCT00020670
View directory record Official record
Conditions
Leukemia
Interventions
CD 40
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Jun 10, 2026, 3:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluating Public Health Interventions to Improve COVID-19 Testing Among Underserved Populations

NCT05270694
View directory record Official record
Conditions
COVID-19
Interventions
Public Health Intervention Package
Behavioral
Lead sponsor
Kathleen Fairfield
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Jun 10, 2026, 3:46 PM EDT
Withdrawn Phase 1Phase 2 Interventional

DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer

NCT00603460
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cancer
Interventions
DCVax-L and T Cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Jun 10, 2026, 3:46 PM EDT
Completed Not applicable Interventional

Wastewater Surveillance to Boost COVID-19 Vaccine Uptake

NCT05766189
View directory record Official record
Conditions
Vaccination, Wastewater Surveillance
Interventions
Wastewater vaccine prompts
Behavioral
Lead sponsor
Syracuse University
Other
Eligibility
Not listed
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Jun 10, 2026, 3:46 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Can Stories Encourage the Elderly to Vaccinate? Combining Viewer-tailored Personal Narrative Videos With Informational Videos to Improve Vaccine Uptake Among Older Adults

NCT06890403
View directory record Official record
Conditions
Vaccination
Interventions
Informational Animation Video, Personal Narrative Video
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
50 Years and older
Enrollment
6,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jun 10, 2026, 3:46 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old

NCT05329961
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Gardasil9
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
4 Years to 8 Years
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Jun 10, 2026, 3:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease

NCT05525546
View directory record Official record
Conditions
Risk Reduction
Interventions
Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation, Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 49 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jun 10, 2026, 3:46 PM EDT
Completed Not applicable Interventional Results available

Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer

NCT00470574
View directory record Official record
Conditions
Breast Cancer
Interventions
QS21, sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine, immunoenzyme technique, immunologic technique, laboratory biomarker analysis
Biological · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Jun 10, 2026, 3:46 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Strengthening Intentions

NCT07222774
View directory record Official record
Conditions
Influenza Vaccination, Behavior And Behavior Mechanism
Interventions
Experimental
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Jun 10, 2026, 3:46 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS)

NCT05677360
View directory record Official record
Conditions
Human Papilloma Virus (HPV) Vaccine
Interventions
HPV MISTICS -Provider Level, HPV MISTICS - Parent Level, HPV MISTICS- HPV Vaccine Champion Level
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Jun 10, 2026, 3:46 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49

NCT04142242
View directory record Official record
Conditions
Meningococcal Infection (Healthy Volunteers)
Interventions
Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Blood sample
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
59 Years and older
Enrollment
471 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
33
States / cities
Chandler, Arizona • San Diego, California • Waterbury, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Jun 10, 2026, 3:46 PM EDT
Completed Phase 1 Interventional

Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome

NCT00270452
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS)
Interventions
WT1 and PR1 Peptide Vaccine
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 3:46 PM EDT
Completed Not applicable Interventional Results available

The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata

NCT00941889
View directory record Official record
Conditions
HIV Positive, Anal Condylomata, Anal Warts, HIV Infections
Interventions
Saline, Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Jun 10, 2026, 3:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Age and Response to Flu Vaccines

NCT03328325
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Virus Quadrivalent Inactivated Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
9 Years to 99 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Jun 10, 2026, 3:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children

NCT00391391
View directory record Official record
Conditions
Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions
Split, Inactivated, Trivalent Influenza Vaccine, Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)
Biological
Lead sponsor
Sanofi
Industry
Eligibility
6 Months to 8 Years
Enrollment
520 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
19
States / cities
Harrisburg, Arkansas • Little Rock, Arkansas • Trumann, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Jun 10, 2026, 3:46 PM EDT